Anika Therapeutics, Inc. is engaged in the osteoarthritis pain management and regenerative solutions space focused on early intervention orthopedics. The Company is leveraging its core expertise in hyaluronic acid and implant solutions. It partners with clinicians to provide minimally invasive products that restore active living for people around the world. It is developing, manufacturing and commercializing products on its hyaluronic acid (HA) technology platform. It is focused on spaces within orthopedics, including osteoarthritis pain management and regenerative solutions, and its products are delivered in key sites of care, including ambulatory surgery centers. Its products include OA Pain Management, Regenerative Solutions, and others. The OA Pain Management product family consists of Cingal, Monovisc, Orthovisc, Orthovisc mini and Orthovisc-T. Its Regenerative Solutions include Integrity, Hyalofast, Tactoset and NanoFx.
종목 코드 ANIK
회사 이름Anika Therapeutics Inc
상장일May 16, 1985
CEOBlanchard (Cheryl Renee)
직원 수288
유형Ordinary Share
회계 연도 종료May 16
주소32 Wiggins Ave
도시BEDFORD
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호01730-2315
전화17814579000
웹사이트https://anika.com/
종목 코드 ANIK
상장일May 16, 1985
CEOBlanchard (Cheryl Renee)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음